quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:30:29·766d
INSIDERFiling
Karuna Therapeutics Inc. logo

Brannan Stephen K. returned $14,059,320 worth of shares to the company (42,604 units at $330.00), closing all direct ownership in the company (SEC Form 4)

KRTX· Karuna Therapeutics Inc.
Health Care
Original source

Companies

  • KRTX
    Karuna Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Dec 12UpdateCitigroup$291.00
  • Dec 12UpdateDeutsche Bank$227.00
  • Aug 22UpdateWells Fargo$225.00
  • Jul 20UpdateMorgan Stanley$280.00
  • Mar 8UpdateCantor Fitzgerald$214.00
  • Jan 27UpdateUBS$209.00

Related

  • PR728d
    PureTech Announces Annual Results for Year Ended December 31, 2023
  • SEC756d
    SEC Form 15-12G filed by Karuna Therapeutics Inc.
  • INSIDER766d
    Healy James returned $466,830,870 worth of shares to the company (1,414,639 units at $330.00), closing all direct ownership in the company (SEC Form 4)
  • INSIDER766d
    Pande Atul returned $326,700 worth of shares to the company (990 units at $330.00), closing all direct ownership in the company (SEC Form 4)
  • INSIDER766d
    Brown Jason Parker returned $6,985,110 worth of shares to the company (21,167 units at $330.00), closing all direct ownership in the company (SEC Form 4)
  • INSIDER766d
    Wheadon David E. returned $326,700 worth of shares to the company (990 units at $330.00), closing all direct ownership in the company (SEC Form 4)
  • INSIDER766d
    Jonas Jeffrey M returned $326,700 worth of shares to the company (990 units at $330.00), closing all direct ownership in the company (SEC Form 4)
  • INSIDER766d
    Olson Laurie J returned $326,700 worth of shares to the company (990 units at $330.00), closing all direct ownership in the company (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022